News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
282,371 Results
Type
Article (15665)
Company Profile (113)
Press Release (266593)
Section
Business (92713)
Career Advice (757)
Deals (16051)
Drug Delivery (66)
Drug Development (39039)
Employer Resources (77)
FDA (6866)
Job Trends (6715)
News (159140)
Policy (15402)
Tag
Academia (707)
Alliances (24680)
Alzheimer's disease (424)
Approvals (6845)
Artificial intelligence (61)
Bankruptcy (149)
Best Places to Work (4772)
Biosimilars (42)
Biotechnology (46)
Breast cancer (47)
Cancer (325)
Career advice (644)
Cell therapy (47)
Clinical research (32060)
Collaboration (144)
Compensation (56)
COVID-19 (934)
C-suite (47)
Data (331)
Diabetes (51)
Diagnostics (1570)
Drug pricing (63)
Earnings (32824)
Employer resources (65)
Events (39208)
Executive appointments (149)
FDA (7046)
Funding (104)
Gene therapy (68)
GLP-1 (296)
Government (1711)
Healthcare (4633)
Infectious disease (955)
Inflammatory bowel disease (52)
Interviews (125)
IPO (6172)
Job creations (2134)
Job search strategy (569)
Layoffs (186)
Legal (3594)
Lung cancer (51)
Manufacturing (93)
Medical device (1973)
Medtech (1975)
Mergers & acquisitions (9901)
Metabolic disorders (160)
Neuroscience (526)
NextGen Class of 2024 (1861)
Non-profit (1003)
Northern California (423)
Obesity (99)
Opinion (126)
Patents (52)
People (29624)
Pharmaceutical (65)
Phase I (8529)
Phase II (13712)
Phase III (11978)
Pipeline (117)
Podcasts (41)
Policy (49)
Postmarket research (1434)
Preclinical (3493)
Radiopharmaceuticals (121)
Rare diseases (94)
Real estate (2788)
Regulatory (10618)
Research institute (797)
Resumes & cover letters (107)
Southern California (433)
Startups (1742)
United States (4262)
Vaccines (137)
Weight loss (77)
Date
Today (76)
Last 7 days (327)
Last 30 days (1173)
Last 365 days (13968)
2024 (12115)
2023 (15553)
2022 (21571)
2021 (22287)
2020 (21914)
2019 (16957)
2018 (13386)
2017 (14929)
2016 (14152)
2015 (16582)
2014 (13270)
2013 (11230)
2012 (12010)
2011 (12527)
2010 (11342)
Location
Africa (367)
Arizona (45)
Asia (21056)
Australia (2770)
California (987)
Canada (581)
China (106)
Connecticut (43)
Europe (41545)
Florida (145)
Illinois (110)
Indiana (82)
Kansas (52)
Maryland (164)
Massachusetts (856)
Minnesota (62)
New Jersey (410)
New York (270)
North Carolina (291)
Northern California (423)
Ohio (42)
Pennsylvania (280)
South America (551)
Southern California (433)
Texas (131)
Washington State (78)
282,371 Results for "essential pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Jazz Pharmaceuticals Provides Update on Phase 2b Trial of Investigational Suvecaltamide (JZP385) in Essential Tremor
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 2b clinical trial (NCT05122650) evaluating the efficacy and safety of suvecaltamide (JZP385), an investigational, highly selective and state-dependent modulator of T-type calcium channels, in adult patients with essential tremor (ET).
June 20, 2024
·
6 min read
Clinical research
Biogen, Sage Scrap Essential Tremor Study After Phase II Failure
Biogen and Sage Therapeutics’ investigational neuroactive steroid did not significantly improve upper limb tremors in patients with essential tremor, the companies announced Wednesday.
July 24, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Essential Pharma Announces the Appointment of Dr Liz Holmes as Chief Medical Officer
October 16, 2024
·
4 min read
Press Releases
Microbix Achieves Essential EU Regulatory Accreditations
October 3, 2024
·
5 min read
Business
Essential Pharma and AcedrA Biopharmaceuticals sign Distribution Agreement to commercialize essential medicines in the Middle East and North Africa region
Essential Pharma, an international specialty pharma group focused on ensuring that patients have sustainable access to low volume, clinically well-established pharmaceutical products across key therapeutic areas, announces that it has signed a Distribution Agreement with AcedrA BioPharmaceuticals (“AcedrA”), a leading Saudi company operating in the Middle East and North Africa region.
March 26, 2024
·
4 min read
Essential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral Capsules
Essential Pharma announces that it has completed the acquisition of Reminyl® oral capsules from Janssen Pharmaceutica NV, a Johnson & Johnson company.
April 17, 2024
·
3 min read
Deals
Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma
Essential Pharma announces that it has completed the acquisition of the entire issued share capital of Renaissance Pharma Ltd.
April 9, 2024
·
5 min read
BioMidwest
People with Essential Tremor May Have Increased Risk of Dementia
Dementia may be three times more common among people with essential tremor, a movement disorder that causes involuntary shaking, than the general population, according to research released March 6, 2024.
March 6, 2024
·
3 min read
Deals
Essential Pharma acquires European rights to Colobreathe®(colistimethate sodium) from Teva
Essential Pharma announces that it has completed the acquisition of European rights to Colobreathe® from Teva Laboratories UK Limited.
January 8, 2024
·
3 min read
Press Releases
Praxis Precision Medicines presents on ulixacaltamide Essential3 program at the Movement Disorders Society 2024 International Congress
September 27, 2024
·
3 min read
1 of 28,238
Next